Panel Discussion: Progressing Ex Vivo Success into Effective In Vivo Therapies

Applying key learnings from ex vivo developments to optimise indication selection, targeting strategies, and clinical translation for in vivo approaches

Discussing the key scientific, regulatory considerations to streamline the integration of in vivo cell therapies into the pipeline

Speakers:

Stefanos Theoharis

Chief Executive Officer

OneChain Immunotherapeutics

Peggy Sotiropoulou

Chief Scientific Officer

T-Knife Therapeutics

Ulf Grawunder

Chief Executive Officer & Co-Founder

T-CURX